

ABSTRACT OF THE DISCLOSURE

Compounds of the present invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The compounds of the present invention are useful as psychotropic drugs
5 in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barr syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the
10 treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. Particular novel compounds of structural formula (I) are also claimed.